Results of a randomized, double-blind placebo controlled phase 3 study evaluating idelalisib in combination with bendamustine and rituximab in patients with relapsed/refractory CLL and adverse prognostic features Meeting Abstract
| Authors: | Barrientos, J. C.; Brown, J. R.; Atallah, E. L.; Coutre, S.; De La Serna, J.; Eradat, H. A.; Farber, C. M.; Janssens, A.; Loscertales, J.; Pocock, C.; Shadman, M.; Adewoye, A. H.; Aiello, M.; Dreiling, L.; Kim, Y.; Zelenetz, A. D.; Stilgenbauer, S. |
| Abstract Title: | Results of a randomized, double-blind placebo controlled phase 3 study evaluating idelalisib in combination with bendamustine and rituximab in patients with relapsed/refractory CLL and adverse prognostic features |
| Meeting Title: | 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 34 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2016 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2016-05-20 |
| Start Page: | 398s |
| Language: | English |
| ACCESSION: | WOS:000404711505028 |
| DOI: | 10.1200/JCO.2016.34.15_suppl.7514 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 7514 -- Source: Wos |
